TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05991882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 1: Craving daily+PBS daily
Description: Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 2: Craving daily+PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 3: Craving trigger+PBS daily
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 4: Craving trigger+PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 5: PBS daily+ PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
Study: NCT05341999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold saline (cryotherapy)
Description: using 20ml of 2.5°C cold saline for 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Final irrigation with normal saline
Description: final irrigation will be done using normal saline at room temperature.
Study: NCT04932603

Intervention type: OTHER
Intervention: Standard of care, with intervention of the multidisciplinary team
Description: Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
Study: NCT05187754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing therapy program
Description: Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
Study: NCT05991882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 6: Craving daily+Craving trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
Study: NCT05874076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy
Study: NCT05494450

Intervention type: DEVICE
Group type: OTHER
Intervention: ExufiberAG+
Description: confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
Study: NCT06253611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV; every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 240 mg IV; every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
Study: NCT05422599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon balm
Description: 300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300mg Maltodextrin capsules
Study: NCT06200077

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Modified Ridge-Splitting
Description: Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Ridge-Splitting
Description: Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Ridge-Splitting
Description: Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
Study: NCT05070910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
Study: NCT05991882

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Condition 8: No daily or trigger craving or PBS
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
Study: NCT06226233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juniver program
Description: The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
Study: NCT05909280

Intervention type: OTHER
Intervention: Pressure-volume loop measurements
Description: Pressure-volume loop measurements using a conductance catheter
Study: NCT02562612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-88
Description: Daily SM-88 in multiple ascending doses over 6 months
Study: NCT05379166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06115083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor re-education using bio-feedback and home training
Description: Pelvic floor re-education using bio-feedback and home training
Study: NCT05729165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novafon® Pro
Description: Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
Study: NCT05529030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salience of Omicron variant
Description: The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salience of Omicron variant
Description: The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-protection message
Description: The message makes a reference to protecting one's self
Study: NCT05475327

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical Therapy
Description: Heating pad~A total of 3 sessions per week were given for 15 to 20 mins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Description: The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins.
Study: NCT06143852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: 12 minute daily guided meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Reduction + Exercise
Description: Reduce social media use at least 30 minutes daily and exercise instead
Study: NCT04982302

Intervention type: PROCEDURE
Intervention: Non-surgical periodontal treatment
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
Study: NCT05007821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Description: One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg (QD)
Description: Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg (TIW)
Description: Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 200 mg
Description: Two 100mg tablets taken orally once daily in the morning during weeks 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 200 mg
Description: Two 100mg tablets taken orally once daily in the morning during weeks 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 100 mg
Description: One 100mg tablet taken orally once daily in the morning during weeks 9-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 100 mg
Description: One 100mg tablet taken orally once daily in the morning during weeks 9-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid 300 mg
Description: Six 50mg tablets taken orally once daily in the morning during weeks 1-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid 300 mg
Description: Six 50mg tablets taken orally once daily in the morning during weeks 1-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine 300 mg
Description: Three 100mg capsules taken orally once daily in the morning during weeks 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine 300 mg
Description: Three 100mg capsules taken orally once daily in the morning during weeks 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg
Description: One 100mg capsule taken orally once daily in the morning during weeks 3-26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg
Description: One 100mg capsule taken orally once daily in the morning during weeks 3-26
Study: NCT05999487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment.
Study: NCT05946616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) combined with behavioral intervention
Description: Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inactive (sham) stimulation combined with behavioral intervention
Description: Inactive (sham) stimulation combined with behavioral intervention (memory interference)
Study: NCT05529030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other-protection message
Description: The message makes a reference to protecting others (patients)
Study: NCT05379166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05456490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine 13.3
Description: Injection into the Intrathecal space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Injection into the Intrathecal space
Study: NCT05618886

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and PFMT
Description: Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
Study: NCT05140837

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychometric hepatic encephalopathy score & Stroop test
Description: MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.

Intervention type: DRUG
Intervention: Drug therapy
Description: Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
Study: NCT05456490

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection into the Intrathecal space
Study: NCT05817682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional education
Description: The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups.
Study: NCT06547411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC Ventilation mode
Description: Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group I received pressure control ventilation (PC).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VC Ventilation mode
Description: Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group II received volume control ventilation (VC).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRVC Ventilation mode
Description: Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group III received pressure-regulated volume control ventilation (PRVC).
Study: NCT06551779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inyección perineural con solución de dextrosa tamponada
Description: Application of perineural injection with buffered dextrose solution, adding 2.5 ml of 7.5% sodium bicarbonate to a 250 ml bottle of glucose solution at 5% concentration, applying 1cc of the solution at different points on the path of the facial nerve.
Study: NCT04514484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT06583473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive digital health application
Description: The study program will provide an integrated interactive digital health application (LINE app on smartphones, incorporating information about biodata recording, health education, questionnaires, and online Q\&A)
Study: NCT04566289

Intervention type: DEVICE
Intervention: PiCSO
Description: Percutaneous coronary intervention
Study: NCT04920799

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beetroot juice
Description: Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate depleted beetroot juice
Description: Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.